6Zhong Xf Yu J, Zhang B, et al. Using ( 18 ) F-flurorodexoyglucose positron emission tomography to estimatethe length of gross tumor in patients with squamous cellcarcinoma of the esophagus[J]. Int J Radiat Oncol Biol Phys,2009,73(1):136-141.
7Erasmus J J, Munden R F. The role of integrated computedtomography position emission tomography in esophageal cancer:staging and assessment of therapeutic response[J]. Semin RadiatOncol,2007,17(1):29-37.
8Van Vliet E P,Heijenbrok-Kal M H, Hunink M G, et al.Staging investigations for esophageal cancer: a meta-analysis[J]. Br J Cancer,2008,98(3):547-557.
9Muijs C T,Schreurs L M,Busz D M, et al. Consequences ofadditional use of information for target volume delineation andradiotherapy dose distribution for esophageal cancer [J].Radiother Oncol,2009,93(3):447-453.
10Vesprini D,Ung Y, Dinniwell R, et al. Improving observervariability in target delineation for gastro-oesophageal cancer the role of (F) fluoro-2-deoxy-D-glucose positron emissiontomography/computed tomography [J]. Clin Oncol, 2008,20(8):631-638.
